A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple Myeloma

A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma

NCT02561962 ·Status: COMPLETED ·Phase: PHASE1

Natural History Study of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Myeloma (SMM)

NCT01109407 ·Status: TERMINATED

Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies

NCT02997813 ·Status: COMPLETED

A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure

NCT05217082 ·Status: COMPLETED

Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide

NCT01301963 ·Status: TERMINATED ·Phase: PHASE3

Multiple Myeloma Patient Registry

NCT03180853 ·Status: TERMINATED

Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission

NCT04221178 ·Status: ACTIVE_NOT_RECRUITING

Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma

NCT05908396 ·Status: TERMINATED ·Phase: PHASE1

S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma

NCT00900263 ·Status: COMPLETED

Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM)

NCT03477643 ·Status: COMPLETED

A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma

NCT03710915 ·Status: TERMINATED ·Phase: PHASE1

SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT01955434 ·Status: COMPLETED ·Phase: PHASE2

Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients

NCT02981199 ·Status: UNKNOWN ·Phase: NA

Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma

NCT01177735 ·Status: COMPLETED ·Phase: PHASE2

Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions

NCT05361694 ·Status: RECRUITING

A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma

NCT01302392 ·Status: COMPLETED ·Phase: PHASE3

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

NCT04892446 ·Status: TERMINATED ·Phase: PHASE2

Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

NCT03267888 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Frontline Therapy in de Novo Multiple Myeloma Patients Under 65

NCT01206205 ·Status: COMPLETED ·Phase: PHASE2

2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy

NCT03000634 ·Status: WITHDRAWN ·Phase: PHASE2

Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy

NCT01676961 ·Status: TERMINATED ·Phase: PHASE2

Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT01946152 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Non-interventional Study on Salvage Auto in Relapsed Myeloma

NCT02439476 ·Status: COMPLETED

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

NCT05312255 ·Status: RECRUITING ·Phase: NA

A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment

NCT04035226 ·Status: COMPLETED